Status: Recruiting
TDM-based Infliximab Treatment for Active Perianal Fistulizing Crohn's Disease
This study will compare the efficacy and safety of TDM (therapeutic drug monitoring)-based infliximab (CT-P13, RemsimaTM) intravenous therapy compared with the standard infliximab (RemsimaTM) intravenous therapy for patients with active perianal fistulzing Crohn's disease.
Participants needed: 86
Trial details
Phase: Phase 4Age: 19-80Biological sex: AllType: InterventionalSponsor: Asan Medical CenterUpdated: May 14, 2024Locations: 1
Eligibility criteria
Age: 19-80 years [+5]
In cases where written informed consents cannot be provided by the study subject... [+23]